XNASRXST
Market cap1.39bUSD
Jan 08, Last price
34.50USD
1D
-3.09%
1Q
-30.86%
IPO
99.19%
Name
Rxsight Inc
Chart & Performance
P/E
—
P/S
15.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
89m
+81.77%
Net income
-49m
L-27.19%
CFO
-42m
L-29.32%
Earnings
Jun 06, 2025
Profile
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 89,077 81.77% | 49,005 116.90% | |||
Cost of revenue | 64,363 | 53,658 | |||
Unusual Expense (Income) | |||||
NOPBT | 24,714 | (4,653) | |||
NOPBT Margin | 27.74% | ||||
Operating Taxes | 20 | 9 | |||
Tax Rate | 0.08% | ||||
NOPAT | 24,694 | (4,662) | |||
Net income | (48,608) -27.19% | (66,756) 37.11% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 105,957 | 5,407 | |||
BB yield | -7.63% | -1.54% | |||
| Debt | |||||
Debt current | 1,801 | 1,970 | |||
Long-term debt | 4,223 | 47,851 | |||
Deferred revenue | |||||
Other long-term liabilities | 74 | ||||
Net debt | (121,869) | (56,742) | |||
| Cash flow | |||||
Cash from operating activities | (41,593) | (58,850) | |||
CAPEX | (4,814) | (2,393) | |||
Cash from investing activities | (22,129) | 39,950 | |||
Cash from financing activities | 61,524 | 6,332 | |||
FCF | 16,853 | (9,313) | |||
| Balance | |||||
Cash | 127,182 | 105,802 | |||
Long term investments | 711 | 761 | |||
Excess cash | 123,439 | 104,113 | |||
Stockholders' equity | (594,609) | (546,099) | |||
Invested Capital | 758,057 | 680,996 | |||
ROIC | 3.43% | ||||
ROCE | 15.12% | ||||
| EV | |||||
Common stock shares outstanding | 34,455 | 27,662 | |||
Price | 40.32 218.23% | 12.67 12.62% | |||
Market cap | 1,389,230 296.38% | 350,477 13.84% | |||
EV | 1,267,361 | 293,735 | |||
EBITDA | 28,957 | (631) | |||
EV/EBITDA | 43.77 | ||||
Interest | 3,308 | 4,946 | |||
Interest/NOPBT | 13.39% | ||||